Facebook
Twitter
Telegram
Report an ErrorGracell Biotechnologies Balance Sheet 2011-2024 | GRCL
Annual Balance Sheet Gracell Biotechnologies
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | -651 M | -169 M | 229 M | - | - | - | - | - | - | - |
Long Term Debt |
- | 51.9 M | 139 M | 139 M | - | - | - | - | - | - | - |
Long Term Debt Current |
- | 970 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | 51.9 M | 139 M | 139 M | - | - | - | - | - | - | - |
Total Current Liabilities |
- | 93.4 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | 145 M | 157 M | 146 M | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | -564 M | -289 M | -81.1 M | - | - | - | - | - | - | - |
Total Assets |
- | 965 M | 412 M | 149 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
- | 754 M | 312 M | 11.9 M | - | - | - | - | - | - | - |
Book Value |
- | 820 M | 255 M | 2.38 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
- | -588 M | -292 M | -81 M | - | - | - | - | - | - | - |
All numbers in CNY currency
Quarterly Balance Sheet Gracell Biotechnologies
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | 53 M | - | 54.3 M | - | - | - | 51.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | 285 M | - | 233 M | - | - | - | 145 M | - | - | - | 157 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | - | -1.32 B | - | -1.02 B | - | - | - | -564 M | - | - | - | -289 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
- | - | 1.9 B | - | 2.06 B | - | - | - | 965 M | - | - | - | 412 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
- | - | 1.54 B | - | 1.83 B | - | - | - | 754 M | - | - | - | 312 M | - | - | - | 11.9 M | - | - | - | 48.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
- | - | 1.61 B | - | 1.83 B | - | - | - | 820 M | - | - | - | 255 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
- | - | 1.61 B | - | 1.83 B | - | - | - | -588 M | - | - | - | -292 M | - | - | - | -81 M | - | - | - | -8.03 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in CNY currency